Sanders-Brown Faculty

Frederick Schmitt, Ph.D.

Professor

Departmental Affiliation(s):

Neurology and Sanders-Brown Center on Aging

Research Focus:

Brain-behavior associations in neurological diseases with a focus on (1) early detection of dementia and (2) outcomes of therapeutic interventions in Alzheimer’s disease. Other projects include behavioral and neuroimaging predictors of HIV dementia, Mild Cognitive Impairment, and descriptions of neuropathological changes in brain with advancing age. He has also developed methods for the evaluation of outcomes in the treatment of brain tumors (brain irradiation). Dr. Schmitt participates as an investigator in a number of clinical trials in Alzheimer’s disease and Mild Cognitive Impairment.

Recent Publications:

Bottiggi KA, Chang JJ, Schmitt FA, Avison MJ, Mootoor Y, Nath A, Berger JR. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci 260: 11-15, 2007.

Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Schmitt FA. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. Am J Geriatr Psychiatry 15: 357-359, 2007.

Nelson KR, Mattingly M, Schmitt FA. Out-of-body experience and arousal. Neurology 68: 794-795, 2007.

Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, Abner EL, Markesbery WR. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol 66: 1136-1146, 2007.

Salazar JC, Schmitt FA, Yu L, Mendiondo MM, Kryscio RJ. Shared random effects analysis of multi-state Markov models: application to a longitudinal study of transitions to dementia. Stat Med 26: 568-580, 2007.

Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68: 1501-1508, 2007.

Schmitt F, Ryan M, Cooper G. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. Expert Opin Drug Metab Toxicol 3: 135-141, 2007.

Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR. Brain structural alterations before mild cognitive impairment. Neurology 68: 1268-1273, 2007.

Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Markesbery WR. Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly. Neurobiol Aging 28: 1075-1087, 2007.

Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 23: 1187-1197, 2007.